Real-World Study Reveals Significant Infection Risks Linked to Antibody-Drug Conjugates in Cancer Patients
Key Insights
A real-world analysis of 3,511 patients across six UC medical centers found certain antibody-drug conjugates (search) are associated with substantial rates of severe neutropenia (search) and febrile neutropenia (search).
The study, published in *Cancers*, evaluated 10 FDA-approved ADCs using data from 2012–2024, revealing wide variability in hematologic toxicity depending on the specific drug used.
Pre-existing conditions such as anemia (search) and immunodeficiency disorders (search) significantly increased patients' risk of serious infection-related complications.
A major real-world investigation led by researchers at the University of California, Irvine has uncovered substantial hematologic toxicities associated with antibody-drug conjugates (search) (ADCs), a rapidly expanding class of targeted cancer therapies. Published by Jan et al in the journal Cancers, the study analyzed treatment data from 3,511 patients across six University of California medical centers, revealing that some widely used ADCs carry significant risks of severe neutropenia (search) and life-threatening infection-related complications.
The findings challenge assumptions about the universal safety of these precision therapies, which are designed to deliver chemotherapy directly to cancer cells while sparing healthy tissue. Although ADCs have improved treatment outcomes for several malignancies, including breast and blood cancers, the real-world data suggest that clinicians must remain alert to potentially serious hematologic side effects.
Real-World Evidence Uncovers Toxicity Patterns
Researchers evaluated 10 commonly prescribed, FDA-approved ADC agents using data collected between 2012 and 2024 through the University of California Health Data Warehouse. This longitudinal approach provided insights beyond the controlled environment of clinical trials, capturing diverse patient demographics, comorbidities, and real clinical practice variables.
The analysis found that rates of severe neutropenia (search)—characterized by dramatically reduced neutrophil counts—and related complications varied widely depending on the specific drug used. Some agents demonstrated a relatively favorable safety spectrum, while others showed markedly elevated risks of severe neutropenia, hospitalization, intensive care admissions, and febrile neutropenia (search), a hazardous syndrome marked by fever and heightened infection vulnerability.
“Our findings demonstrate that while ADCs offer tremendous promise for cancer patients, clinicians must remain vigilant about potentially serious hematologic toxicities,” said corresponding author Alexandre Chan, PharmD, PhD, Professor and Chair of Clinical Pharmacy Practice at UCI School of Pharmacy & Pharmaceutical Sciences. “Using real-world data allows us to understand better how these therapies affect diverse patient populations outside the controlled environment of clinical trials.”
Patient-Specific Risk Factors Identified
The study also highlighted that underlying conditions significantly influenced patient outcomes. Pre-existing anemia (search) and immunodeficiency disorders (search) emerged as notable risk enhancers for adverse events, underscoring the critical need for individualized risk stratification before initiating ADC-based regimens.
This heterogeneity in toxicity profiles suggests that a one-size-fits-all monitoring approach may be insufficient. The researchers advocate for integrating predictive analytics and biomarker-driven patient selection to identify individuals at elevated risk of neutropenic complications prior to therapy initiation.
Implications for Clinical Practice
As the portfolio of FDA-approved ADC therapies continues to expand across oncology indications, the study’s findings carry broad implications. The authors emphasize that robust hematologic monitoring frameworks and timely supportive interventions—including prophylactic use of growth factors or antimicrobial agents—should accompany ADC administration.
“As these targeted therapies become more widely used, understanding and anticipating side effects becomes increasingly important,” Dr. Chan said. “This work can help inform safer treatment strategies and improve patient outcomes.”
The collaborative effort spanned multiple University of California campuses and health systems, with contributions from the University of Washington, exemplifying the multidisciplinary approach necessary to unravel the complexities of ADC toxicity. The synergy between clinical pharmacy, oncology, data science, and patient care teams was instrumental in generating actionable insights from vast healthcare datasets.
Ultimately, the investigation signals that the transformative potential of ADCs must be tempered by a pragmatic understanding of their hematologic risks. As precision medicine advances, integrating real-world safety data will be fundamental in shaping adaptive treatment algorithms that balance efficacy with toxicity mitigation.